rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    CATX
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Perspective Therapeutics CMO Markus Puhlmann buys $34,544 in stock
      Nov 13Investing.comCATX
      Perspective Therapeutics Analysts Slash Their Forecasts After Q3 Results
      Nov 10BenzingaCATX
      BMO reiterates Outperform on Perspective Therapeutics stock
      Nov 10Investing.comCATX
      Wedbush lowers Perspective Therapeutics stock price target to $7
      Nov 10Investing.comCATX
      Truist cuts Perspective Therapeutics stock price target on timeline
      Nov 10Investing.comCATX
      Perspective Therapeutics earnings missed by $0.03, revenue fell short of estimates
      Nov 10Investing.comCATX
      Perspective Therapeutics: Q3 Earnings Snapshot
      Nov 9Yahoo FinanceCATX
      Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2026 Results
      Nov 9Yahoo FinanceCATX
      Perspective Therapeutics (CATX) Stock Sees Fair Value Moves Lower As Analysts Weigh Lead 212 Risks
      Nov 1Yahoo FinanceCATX
      BMO reiterates Perspective Therapeutics stock rating on platform strength
      Oct 30Investing.comCATX
      Analysts Are Bullish on Top Healthcare Stocks: Perspective Therapeutics (CATX), Oric Pharmaceuticals (ORIC)

      Tipranks Press Release.

      Oct 27The Globe and MailCATX
      Perspective Therapeutics Facing Execution Risks in Bamzireotide Navoxetan's Development, RBC Says
      Oct 26Yahoo FinanceCATX
      RBC Downgrades Perspective Therapeutics to Sector Perform From Outperform, Cuts Price Target to $4 From $14, Keeps Speculative Risk
      Oct 26Yahoo FinanceCATX
      BTIG reiterates Buy on Perspective Therapeutics stock after data
      Oct 26Investing.comCATX
      RBC Capital downgrades Perspective Therapeutics stock rating on trial data
      Oct 26Investing.comCATX
      Wedbush Adjusts Price Target on Perspective Therapeutics to $9 From $11, Keeps Outperform Rating
      Oct 26Yahoo FinanceCATX
      Perspective Therapeutics Posts 72% 18-Month PFS in VMT-α-NET Study Update
      Oct 23Yahoo FinanceCATX
      Perspective Therapeutics reports interim trial results for NET cancer treatment
      Oct 23Investing.comCATX
      Perspective’s [212Pb]Bamzireotide Navoxetan (VMT-α-NET) Demonstrates Encouraging Safety, Durable Disease Control, and Robust Tumor Response Across Multiple Dose Cohorts in Phase 1/2a Trial in Advanced SSTR2-Expressing NETs

      Results presented at ESMO show a promising therapeutic index for [212Pb]VMT-α-NETDurable disease control in all three cohorts and 72% PFS at 18 months across all patients who received at least one treatmentRobust activity observed at three dose levels across patient populations, with ORRs of 33% and 50% in Cohorts 2 and 3, respectively; higher responses were observed in Cohort 3 relative to Cohort 2 at early assessments [212Pb]VMT-α-NET continues to be well-tolerated, with no DLTs, and no discon

      Oct 23Yahoo FinanceCATX
      Perspective Therapeutics (CATX) Gets a Hold from Bank of America Securities

      Tipranks Press Release.

      Oct 20The Globe and MailCATX
      Perspective Therapeutics (CATX) Receives a Buy from Wedbush

      Detailed price information for Perspective Therapeutics Inc (CATX-A) from The Globe and Mail including charting and trades.

      Oct 14The Globe and MailCATX
      Perspective Therapeutics Granted Fast Track Designation for [212Pb]PSV359 for the Treatment of Adult Patients with Locally Advanced Unresectable and/or Metastatic FAP-Positive Solitary Fibrous Tumors
      Oct 8Yahoo FinanceCATX
      Wedbush Reaffirms Their Buy Rating on Perspective Therapeutics (CATX)

      Tipranks Press Release.

      Sep 26The Globe and MailCATX
      This $3 Biotech Could Be Worth $11.45, Analyst Says
      Sep 18BenzingaCATX
      William Blair initiates Perspective Therapeutics stock with outperform rating
      Sep 18Investing.comCATX
      William Blair Initiates Perspective Therapeutics With Outperform Rating
      Sep 18Yahoo FinanceCATX
      Perspective Therapeutics at Morgan Stanley conference: alpha-drug push
      Sep 16Investing.comMSCATX
      Analysts Conflicted on These Healthcare Names: Sarepta Therapeutics (SRPT), Addus Homecare (ADUS) and Perspective Therapeutics (CATX)

      Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.

      Sep 16The Globe and MailADUSCATX
      Perspective Therapeutics partners with Merck on cancer trial
      Sep 14Investing.comMRKCATX
      Perspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212Pb]PSV359 in Combination with Keytruda® (Pembrolizumab) in FAP-α Positive Solid Tumors

      SEATTLE, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced a clinical trial collaboration agreement with Merck (NYSE: MRK), known as MSD outside of the United States and Canada. The agreement supports the evaluation of Perspective’s targeted alpha-particle therapy [212Pb]PSV359 in com

      Sep 14Yahoo FinanceCATX
      Perspective Therapeutics Enters Cancer Clinical Trial Collaboration With Merck; Shares Up Pre-Bell

      Perspective Therapeutics (CATX) has signed a clinical trial collaboration with Merck (MRK) for the p

      Sep 14Yahoo FinanceCATX
      Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the 38th EORTC-NCI-AACR Symposium 2026

      SEATTLE, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that updated data on the Company’s [212Pb]VMT-α-NET program have been accepted for presentation as detailed below at the 38th EORTC-NCI-AACR (ENA) Symposium 2026 on Molecular Targets and Cancer Therapeutics taking place Novemb

      Sep 11Yahoo FinanceCATX
      Perspective Therapeutics Updates Radiopharmaceutical Oncology Pipeline Outlook

      Detailed price information for Perspective Therapeutics Inc (CATX-A) from The Globe and Mail including charting and trades.

      Sep 9The Globe and MailCATX
      Lantheus Holdings sells $245,609 in Perspective Therapeutics stock
      Sep 2Investing.comLNTHCATX
      Perspective Therapeutics: 'Strong Buy' On Bamzireotide Navoxetan Reinforced Data

      Perspective Therapeutics is rated Strong Buy on durable radiopharmaceutical data, $237M cash runway, and key 2026 catalysts. Click here to read more.

      Sep 1Seeking AlphaCATX

      This is the newest page. Registered accounts read further back.